Skip to content

Efficacy and Safety of Pulsed Field Ablation (PFA) Versus Radiofrequency Ablation (RFA) for the Treatment of Ventricular Arrhythmias: A Non-Inferiority, Multicenter, Prospective, Randomized Controlled Trial

Efficacy and Safety of Pulsed Field Ablation (PFA) Versus Radiofrequency Ablation (RFA) for the Treatment of Ventricular Arrhythmias: A Non-Inferiority, Multicenter, Prospective, Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107500
Enrollment
Unknown
Registered
2025-08-13
Start date
2025-09-10
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular arrhythmia

Interventions

Pulse ablation group:Use of a disposable magnetic field-guided pressure-monitoring Pulsed Field Ablation catheter (Huikang) in combination with the HT-9000 PRO 3D mapping system
Radiofrequency ablation group:Use of ThermoCool SmartTouch ST or SF catheter for standard radiofrequency ablation with usual power settings

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age >=18 years. (2) Drug-refractory idiopathic PVCs with a 24-h Holter burden = 10 % or sustained monomorphic VT (>= 3 beats) documented on ECG or EP study. (3)Ability to provide written informed consent

Exclusion criteria

Exclusion criteria: (1)Hemodynamically unstable heart failure (e.g., NYHAClass III-IV or acute decompensation) or severe valvular heart disease requiring surgical intervention. (2)Prior history of aborted sudden cardiac death (SCD) or survivors of cardiac arrest. (3)Pregnancy or lactation. (4)Implanted cardioverter-defibrillator (ICD) with a history of frequent appropriate or inappropriate shocks within the recent [3/6] months. (5)Severe hepatic or renal impairment, defined as: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN); serum creatinine (SCr) >3.5 mg/dL; or calculated creatinine clearance (CrCl) <30 mL/min. (6)Known contraindications to radiofrequency ablation, electrophysiology (EP) study, or anticoagulation therapy contraindications.

Design outcomes

Primary

MeasureTime frame
The primary efficacy endpoint is sustained arrhythmia-free survival at 6 months;The primary safety endpoint is the incidence of Major Adverse Cardiac Events (MACE) within 30 days post-procedure;

Secondary

MeasureTime frame
Surgical efficiency: total procedure time, fluoroscopy time and radiation dose (mGy value);Pain assessment (VAS);Quality of life (SF-36);

Countries

China

Contacts

Public ContactChen Yanbo

Weifang People's Hospital

cyb0222@126.com+86 151 6646 0788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026